413 related articles for article (PubMed ID: 34391887)
1. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
2. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
[TBL] [Abstract][Full Text] [Related]
3. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
4. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S
J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780
[TBL] [Abstract][Full Text] [Related]
5. MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design.
Cai W; Zhou D; Wu W; Tan WL; Wang J; Zhou C; Lou Y
BMC Genomics; 2018 Aug; 19(1):582. PubMed ID: 30075702
[TBL] [Abstract][Full Text] [Related]
6. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes.
Chong C; Müller M; Pak H; Harnett D; Huber F; Grun D; Leleu M; Auger A; Arnaud M; Stevenson BJ; Michaux J; Bilic I; Hirsekorn A; Calviello L; Simó-Riudalbas L; Planet E; Lubiński J; Bryśkiewicz M; Wiznerowicz M; Xenarios I; Zhang L; Trono D; Harari A; Ohler U; Coukos G; Bassani-Sternberg M
Nat Commun; 2020 Mar; 11(1):1293. PubMed ID: 32157095
[TBL] [Abstract][Full Text] [Related]
7. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
9. Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Gao S; Gong T; Bahta M; Venugopalan A; Zhang X; Guha U
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638461
[TBL] [Abstract][Full Text] [Related]
10. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma.
Pan D; Zhou D; Cai W; Wu W; Tan WL; Zhou C; Lou Y
BMC Immunol; 2019 Nov; 20(1):43. PubMed ID: 31722672
[TBL] [Abstract][Full Text] [Related]
12. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
Ghorani E; Rosenthal R; McGranahan N; Reading JL; Lynch M; Peggs KS; Swanton C; Quezada SA
Ann Oncol; 2018 Jan; 29(1):271-279. PubMed ID: 29361136
[TBL] [Abstract][Full Text] [Related]
13. Large-Scale Immunopeptidome Analysis Reveals Recurrent Posttranslational Splicing of Cancer- and Immune-Associated Genes.
Levy R; Alter Regev T; Paes W; Gumpert N; Cohen Shvefel S; Bartok O; Dayan-Rubinov M; Alon M; Shmueli MD; Levin Y; Merbl Y; Ternette N; Samuels Y
Mol Cell Proteomics; 2023 Apr; 22(4):100519. PubMed ID: 36828127
[TBL] [Abstract][Full Text] [Related]
14. The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides.
Bedran G; Gasser HC; Weke K; Wang T; Bedran D; Laird A; Battail C; Zanzotto FM; Pesquita C; Axelson H; Rajan A; Harrison DJ; Palkowski A; Pawlik M; Parys M; O'Neill JR; Brennan PM; Symeonides SN; Goodlett DR; Litchfield K; Fahraeus R; Hupp TR; Kote S; Alfaro JA
Cancer Immunol Res; 2023 Jun; 11(6):747-762. PubMed ID: 36961404
[TBL] [Abstract][Full Text] [Related]
15. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
[TBL] [Abstract][Full Text] [Related]
16. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
[TBL] [Abstract][Full Text] [Related]
18. PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity.
Liu G; Li D; Li Z; Qiu S; Li W; Chao CC; Yang N; Li H; Cheng Z; Song X; Cheng L; Zhang X; Wang J; Yang H; Ma K; Hou Y; Li B
Gigascience; 2017 May; 6(5):1-11. PubMed ID: 28327987
[TBL] [Abstract][Full Text] [Related]
19. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
20. An
Lin J; Liu J; Hao SG; Lan B; Zheng XB; Xiong JN; Zhang YQ; Gao X; Chen CB; Chen L; Huang YF; Luo H; Yi YT; Yi X; Lu JP; Zheng XW; Chen G; Wang XF; Chen Y
Front Immunol; 2022; 13():1022598. PubMed ID: 36505399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
